We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
For the first time, 2- to 5-year-old patients with a certain type of cystic fibrosis could access cystic fibrosis drugs Kaftrio and Kalydeco.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
Besins Healthcare (UK) Ltd has informed the MHRA that a defective pump system was detected in two batches of Oestrogel Pump-Pack 750 micrograms/actuation Gel.
Fake, potentially harmful Ozempic and Saxenda pens have been found in the UK: you should only access these medicines via a medical prescription.
No evidence of supply or harm to patients
Falsified, potentially harmful Ozempic▼ and Saxenda products have been found in the UK.
The eMIT provides information about prices and usage for generic drugs and pharmaceutical products.
A summary of recent letters and notifications sent to healthcare professionals about medicines, and a recent National Patient Safety Alert highlighting the risk of deaths and serious injuries from entrapment or falls relating to medical beds, bed rails, trolleys, bariatric...
Veriton Pharma Limited is recalling a specific batch of Epistatus (midazolam) 2.5mg Oromucosal Solution (pre-filled oral syringes) due to confirmed out of specification results related to the product appearance.
Department of Health and Social Care and MHRA register of electronic export certificates (human).
Novartis Pharmaceuticals UK Limited is recalling Adakveo 10 mg/ml concentrate for solution for infusion due to the benefit-risk balance of Adakveo no longer being considered favourable by the MHRA.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).